These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 34653245)

  • 41. Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial.
    Li JX; Hou LH; Meng FY; Wu SP; Hu YM; Liang Q; Chu K; Zhang Z; Xu JJ; Tang R; Wang WJ; Liu P; Hu JL; Luo L; Jiang R; Zhu FC; Chen W
    Lancet Glob Health; 2017 Mar; 5(3):e324-e334. PubMed ID: 28017642
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.
    Lei H; Peng X; Jiao H; Zhao D; Ouyang J
    Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial.
    Jin P; Guo X; Chen W; Ma S; Pan H; Dai L; Du P; Wang L; Jin L; Chen Y; Shi F; Liu J; Xu X; Zhang Y; Gao GF; Chen C; Feng J; Li J; Zhu F
    PLoS Med; 2022 May; 19(5):e1003953. PubMed ID: 35617368
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunogenicity and safety of an AS03-adjuvanted H5N1 pandemic influenza vaccine in Korean adults: a phase IV, randomized, open-label, controlled study.
    Izurieta P; Kim WJ; Wie SH; Lee J; Lee JS; Dramé M; Vaughn DW; Schuind A
    Vaccine; 2015 Jun; 33(24):2800-7. PubMed ID: 25910919
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults.
    Turley CB; Rupp RE; Johnson C; Taylor DN; Wolfson J; Tussey L; Kavita U; Stanberry L; Shaw A
    Vaccine; 2011 Jul; 29(32):5145-52. PubMed ID: 21624416
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial.
    Palacios R; Patiño EG; de Oliveira Piorelli R; Conde MTRP; Batista AP; Zeng G; Xin Q; Kallas EG; Flores J; Ockenhouse CF; Gast C
    Trials; 2020 Oct; 21(1):853. PubMed ID: 33059771
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial.
    Cadorna-Carlos JB; Nolan T; Borja-Tabora CF; Santos J; Montalban MC; de Looze FJ; Eizenberg P; Hall S; Dupuy M; Hutagalung Y; Pépin S; Saville M
    Vaccine; 2015 May; 33(21):2485-92. PubMed ID: 25843270
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial.
    Liang XF; Wang HQ; Wang JZ; Fang HH; Wu J; Zhu FC; Li RC; Xia SL; Zhao YL; Li FJ; Yan SH; Yin WD; An K; Feng DJ; Cui XL; Qi FC; Ju CJ; Zhang YH; Guo ZJ; Chen PY; Chen Z; Yan KM; Wang Y
    Lancet; 2010 Jan; 375(9708):56-66. PubMed ID: 20018364
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical testing of an inactivated influenza A/H5N1 vaccine candidate in a double-blinded, placebo-controlled, randomized trial in healthy adults in Vietnam.
    Phan TL; Ho VT; Vu MH; Nguyen TN; Duong HT; Holt R; Wahid R; Donnelly J; Flores J
    Vaccine; 2016 Oct; 34(45):5449-5456. PubMed ID: 27591953
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: a phase 1-2 randomised controlled trial.
    Folschweiller N; Vanden Abeele C; Chu L; Van Damme P; García-Sastre A; Krammer F; Nachbagauer R; Palese P; Solórzano A; Bi D; David MP; Friel D; Innis BL; Koch J; Mallett CP; Rouxel RN; Salaun B; Vantomme V; Verheust C; Struyf F
    Lancet Infect Dis; 2022 Jul; 22(7):1062-1075. PubMed ID: 35461522
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations.
    Frey SE; Bernstein DI; Brady RC; Keitel WA; El Sahly H; Rouphael NG; Mulligan MJ; Atmar RL; Edupuganti S; Patel SM; Dickey M; Graham I; Anderson EL; Noah DL; Hill H; Wolff M; Belshe RB
    Vaccine; 2015 Jan; 33(1):163-73. PubMed ID: 25444805
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A randomized Phase I/II study to evaluate safety and reactogenicity of a heat-stable rotavirus vaccine in healthy adults followed by evaluation of the safety, reactogenicity, and immunogenicity in infants.
    Kanchan V; Zaman K; Aziz AB; Zaman SF; Zaman F; Haque W; Khanam M; Karim MM; Kale S; Ali SK; Goveia MG; Kaplan SS; Gill D; Khan WA; Yunus M; Singh A; Clemens JD
    Hum Vaccin Immunother; 2020 Mar; 16(3):693-702. PubMed ID: 31526218
    [No Abstract]   [Full Text] [Related]  

  • 53. Safety and immunogenicity of a replication-deficient H5N1 influenza virus vaccine lacking NS1.
    Nicolodi C; Groiss F; Kiselev O; Wolschek M; Seipelt J; Muster T
    Vaccine; 2019 Jun; 37(28):3722-3729. PubMed ID: 31155415
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in healthy adults: an observer-blind, randomised, phase 1 trial.
    Han HH; Diaz C; Acosta CJ; Liu M; Borkowski A
    Lancet Infect Dis; 2021 Sep; 21(9):1282-1292. PubMed ID: 34019802
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunogenicity and Safety of Reduced-Dose Intradermal vs Intramuscular Influenza Vaccines: A Systematic Review and Meta-analysis.
    Egunsola O; Clement F; Taplin J; Mastikhina L; Li JW; Lorenzetti DL; Dowsett LE; Noseworthy T
    JAMA Netw Open; 2021 Feb; 4(2):e2035693. PubMed ID: 33560425
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Induction of Cross-Reactive Hemagglutination Inhibiting Antibody and Polyfunctional CD4+ T-Cell Responses by a Recombinant Matrix-M-Adjuvanted Hemagglutinin Nanoparticle Influenza Vaccine.
    Shinde V; Cai R; Plested J; Cho I; Fiske J; Pham X; Zhu M; Cloney-Clark S; Wang N; Zhou H; Zhou B; Patel N; Massare MJ; Fix A; Spindler M; Thomas DN; Smith G; Fries L; Glenn GM
    Clin Infect Dis; 2021 Dec; 73(11):e4278-e4287. PubMed ID: 33146720
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase I, randomized, controlled trial to study the reactogenicity and immunogenicity of a nasal, inactivated trivalent influenza virus vaccine in healthy adults.
    Halperin SA; Smith B; Clarke K; Treanor J; Mabrouk T; Germain M
    Hum Vaccin; 2005; 1(1):37-42. PubMed ID: 17038827
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety, tolerability, acceptability and immunogenicity of an influenza vaccine delivered to human skin by a novel high-density microprojection array patch (Nanopatch™).
    Fernando GJP; Hickling J; Jayashi Flores CM; Griffin P; Anderson CD; Skinner SR; Davies C; Witham K; Pryor M; Bodle J; Rockman S; Frazer IH; Forster AH
    Vaccine; 2018 Jun; 36(26):3779-3788. PubMed ID: 29779922
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase III, randomized controlled trial to evaluate lot consistency of a trivalent subunit egg-based influenza vaccine in adults.
    Rivera L; Mazara S; Vargas M; Fragapane E; Casula D; Groth N
    Vaccine; 2012 Jul; 30(35):5285-92. PubMed ID: 22659448
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of safety and immunogenicity of HNVAC, an MDCK-based H1N1 pandemic influenza vaccine, in Phase I single centre and Phase II/III multi-centre, double-blind, randomized, placebo-controlled, parallel assignment studies.
    Basavaraj VH; Sampath G; Hegde NR; Mohan VK; Ella KM
    Vaccine; 2014 Jul; 32(35):4592-4597. PubMed ID: 24856782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.